Evidence map›Paper›PMID 27586591›Full record

ArticleScientific reports2016

Identification and functional characterization of the miRNA-gene regulatory network in chronic myeloid leukemia lineage negative cells.

S Agatheeswaran, N C Pattnayak, S Chakraborty

Abstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

S AgatheeswaranInstitute of Life Sciences, Nalco Square, Bhubaneswar, Odisha, India.
N C PattnayakDepartment of Clinical Haematology, SCB Medical College, Cuttack, Odisha, India.
S ChakrabortyInstitute of Life Sciences, Nalco Square, Bhubaneswar, Odisha, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic myeloid leukemia (CML) is maintained by leukemic stem cells (LSCs) which are resistant to the existing TKI therapy. Hence a better understanding of the CML LSCs is necessary to eradicate these cells and achieve complete cure. Using the miRNA-gene interaction networks from the CML lin(-) cells we identified a set of up/down-regulated miRNAs and corresponding target genes. Association studies (Pearson correlation) from the miRNA and gene expression data showed that miR-1469 and miR-1972 have significantly higher number of target genes, 75 and 50 respectively. We observed that miR-1972 induces G2-M cell cycle arrest and miR-1469 moderately arrested G1 cell cycle when overexpressed in KCL22 cells. We have earlier shown that a combination of imatinib and JAK inhibitor I can significantly bring down the proliferation of CML lineage negative cells. Here we observed that imatinib and JAK inhibitor I combination restored the expression pattern of the down-regulated miRNAs in primary CML lin(-) cells. Thus effective manipulation of the deregulated miRNAs can restore the miRNA-mRNA networks that can efficiently inhibit CML stem and progenitor cells and alleviate the disease.

Indexed as

Gene Regulatory Networks3' Untranslated RegionsAdaptor Proteins, Signal TransducingBase Sequencecdc25 PhosphatasesCell LineageG1 Phase Cell Cycle CheckpointsG2 Phase Cell Cycle CheckpointsGene Expression ProfilingGene Expression Regulation, LeukemicHumansImatinib MesylateLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMicroRNAsNeoplastic Stem CellsNuclear Proteins3' Untranslated RegionsAdaptor Proteins, Signal TransducingCDC25B protein, humancdc25 PhosphatasesCRKL proteinImatinib MesylateMicroRNAsNuclear ProteinsRNA, Messenger

Identifiers

PMID27586591
PMCPMC5009428

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.